Literature DB >> 25224291

Magnitude of fragility fracture risk in the very old--are we meeting their needs? The Newcastle 85+ Study.

R Duncan1, R M Francis, C Jagger, A Kingston, E McCloskey, J Collerton, L Robinson, T B L Kirkwood, F Birrell.   

Abstract

UNLABELLED: Fractures due to osteoporosis are common in older people. This study assessed the management of osteoporosis in a group of 85-year-olds and found both assessment and current treatment to be suboptimal.
INTRODUCTION: Fragility fractures are a major cause of excess mortality, substantial morbidity, and health and social service expenditure in older people. However, much less is known about fracture risk and its management in the very old, despite this being the fastest growing age group of our population.
METHODS: Cross-sectional analysis of people who reached the age of 85 during the year of 2006 was carried out. Data were gathered by general practice record review (GPRR) and a multidimensional health assessment (MDHA).
RESULTS: Seven hundred thirty-nine individuals were recruited. Mean age was 85.55 years (SD 0.44), and 60.2% were female; 33.7% (n = 249) had experienced one or more fragility fractures (F 45.2% vs M 16.3% p < 0.001); in total, 332 fractures occurred in these 249 individuals. A formal documented diagnosis of osteoporosis occurred in 12.4%, and 38% of individuals had experienced a fall in the last 12 months. When the fracture risk assessment tool (FRAX) and National Osteoporosis Guideline Group (NOGG) guidelines were applied, osteoporosis treatment would be recommended in 35.0%, with a further 26.1% identified as needing bone mineral density (BMD) measurement and 38.9% not requiring treatment or BMD assessment. Women were more likely than men to need treatment (47.4 vs 16.3%, p < 0.001, odds ratio (OR) 4.62 (3.22-5.63)) and measurement of BMD (40.0 vs 5.1%, p < 0.001, OR 12.4 (7.13-21.6)). Of the 259 individuals identified as requiring treatment, only 74 (28.6%) were on adequate osteoporosis treatment.
CONCLUSION: The prevalence of high fracture risk in the very old is much higher than the documented diagnosis of osteoporosis or the use of adequate treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224291     DOI: 10.1007/s00198-014-2837-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  17 in total

Review 1.  Adherence to treatment of osteoporosis: a need for study.

Authors:  F Lekkerkerker; J A Kanis; N Alsayed; G Bouvenot; N Burlet; D Cahall; A Chines; P Delmas; R-L Dreiser; D Ethgen; N Hughes; J-M Kaufman; S Korte; G Kreutz; A Laslop; B Mitlak; V Rabenda; R Rizzoli; A Santora; R Schimmer; Y Tsouderos; P Viethel; J-Y Reginster
Journal:  Osteoporos Int       Date:  2007-06-22       Impact factor: 4.507

2.  Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients' self-reports and on determinants of inaccuracy.

Authors:  D M Kriegsman; B W Penninx; J T van Eijk; A J Boeke; D J Deeg
Journal:  J Clin Epidemiol       Date:  1996-12       Impact factor: 6.437

3.  Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement.

Authors:  Crystal F Simpson; Cynthia M Boyd; Michelle C Carlson; Michael E Griswold; Jack M Guralnik; Linda P Fried
Journal:  J Am Geriatr Soc       Date:  2004-01       Impact factor: 5.562

4.  Pharmacological treatments for osteoporosis in very elderly people.

Authors:  Wei Mei Chua; Novoneel Nandi; Tahir Masud
Journal:  Ther Adv Chronic Dis       Date:  2011-07       Impact factor: 5.091

5.  Fracture incidence in England and Wales: a study based on the population of Cardiff.

Authors:  A Johansen; R J Evans; M D Stone; P W Richmond; S V Lo; K W Woodhouse
Journal:  Injury       Date:  1997 Nov-Dec       Impact factor: 2.586

6.  Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Arch Osteoporos       Date:  2009-03-19       Impact factor: 2.617

7.  Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study.

Authors:  L Huot; C M Couris; V Tainturier; S Jaglal; C Colin; A-M Schott
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 4.507

8.  Falls among older general practice patients: a 2-year nationwide surveillance study.

Authors:  Nicole Boffin; Sarah Moreels; Katrien Vanthomme; Viviane Van Casteren
Journal:  Fam Pract       Date:  2014-02-15       Impact factor: 2.267

9.  Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec.

Authors:  Alain Vanasse; Pierre Dagenais; Théophile Niyonsenga; Jean-Pierre Grégoire; Josiane Courteau; Abbas Hemiari
Journal:  BMC Musculoskelet Disord       Date:  2005-06-21       Impact factor: 2.362

10.  The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol.

Authors:  Joanna Collerton; Karen Barrass; John Bond; Martin Eccles; Carol Jagger; Oliver James; Carmen Martin-Ruiz; Louise Robinson; Thomas von Zglinicki; Tom Kirkwood
Journal:  BMC Geriatr       Date:  2007-06-26       Impact factor: 3.921

View more
  3 in total

1.  The association of falls with loneliness and social exclusion: evidence from the DEAS German Ageing Survey.

Authors:  André Hajek; Hans-Helmut König
Journal:  BMC Geriatr       Date:  2017-09-05       Impact factor: 3.921

2.  Comment on an article: "Osteoporosis in the age of COVID-19 patients".

Authors:  O Ć Ibrahimagić; A Vujadinović; Z Ercegović; S Kunić; Dž Smajlović; Z Dostović
Journal:  Osteoporos Int       Date:  2021-01-21       Impact factor: 4.507

3.  Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women.

Authors:  Bernhard Steiner; Hans Peter Dimai; Hubert Steiner; Sabrina Cirar; Astrid Fahrleitner-Pammer
Journal:  J Ultrasound Med       Date:  2018-10-20       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.